These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21137179)

  • 21. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
    Perzborn E
    Hamostaseologie; 2009 Aug; 29(3):260-7. PubMed ID: 19644596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
    Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
    J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
    Kakar P; Watson T; Lip GY
    Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rivaroxaban. The first factor Xa inhibitor].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2008 Nov; 31(11):412-6. PubMed ID: 19055160
    [No Abstract]   [Full Text] [Related]  

  • 27. Determination of rivaroxaban in human plasma samples.
    Harenberg J; Erdle S; Marx S; Krämer R
    Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New antithrombotic drugs: potential for use in oncology.
    Levine MN
    J Clin Oncol; 2009 Oct; 27(29):4912-8. PubMed ID: 19738103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.
    Wagner NM; Dressel T; Schäfer K; Konstantinides S
    Thromb Res; 2012 Nov; 130(5):793-8. PubMed ID: 22281071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clot prevention--common questions about medications.
    Tadros R; Shakib S
    Aust Fam Physician; 2010 Jul; 39(7):480-3. PubMed ID: 20628661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
    Chen T; Lam S
    Cardiol Rev; 2009; 17(4):192-7. PubMed ID: 19525681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
    Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
    J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The discovery and development of rivaroxaban.
    Misselwitz F; Berkowitz SD; Perzborn E
    Ann N Y Acad Sci; 2011 Mar; 1222():64-75. PubMed ID: 21434944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
    Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y
    Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral Xa inhibitors.
    Romualdi E; Ageno W
    Hematol Oncol Clin North Am; 2010 Aug; 24(4):727-37, viii-ix. PubMed ID: 20659657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
    Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
    J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
    Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
    Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
    J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.